Arrowhead Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Arrowhead Pharmaceuticals Inc cash flow-to-debt ratio. Arrowhead Pharmaceuticals Inc (ARWR) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of $20.49 Million could theoretically repay 0% of its total liabilities ($881.88 Million) in one year. Check cash flow reinvestment rate of Arrowhead Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Arrowhead Pharmaceuticals Inc (1997–2025)
Cash flow-to-debt ratio of Arrowhead Pharmaceuticals Inc from 1997 to 2025. Historical debt coverage capacity for Arrowhead Pharmaceuticals Inc across 29 annual periods. Check Arrowhead Pharmaceuticals Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Arrowhead Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1997–2025)
Arrowhead Pharmaceuticals Inc cash flow-to-debt ratio by year from 1997 to 2025. Year-by-year debt coverage analysis for Arrowhead Pharmaceuticals Inc. For the full cash flow conversion analysis, see ARWR cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | $179.55 Million | $947.02 Million | ▲ +138.9% |
| 2024 | -0.49x | $-462.85 Million | $948.74 Million | ▼ -51.7% |
| 2023 | -0.32x | $-153.89 Million | $478.39 Million | ▲ +35.3% |
| 2022 | -0.50x | $-136.13 Million | $273.60 Million | ▼ -187.6% |
| 2021 | 0.57x | $171.22 Million | $301.33 Million | ▲ +136.2% |
| 2020 | -1.57x | $-95.39 Million | $60.72 Million | ▼ -196.1% |
| 2019 | 1.64x | $173.03 Million | $105.81 Million | ▲ +156.7% |
| 2018 | -2.88x | $-47.22 Million | $16.37 Million | ▼ -179.0% |
| 2017 | -1.03x | $-23.94 Million | $23.16 Million | ▲ +46.8% |
| 2016 | -1.94x | $-64.43 Million | $33.15 Million | ▲ +33.0% |
| 2015 | -2.90x | $-65.71 Million | $22.65 Million | ▼ -37.9% |
| 2014 | -2.10x | $-35.42 Million | $16.83 Million | ▼ -28.2% |
| 2013 | -1.64x | $-19.03 Million | $11.59 Million | ▲ +17.4% |
| 2012 | -1.99x | $-15.34 Million | $7.72 Million | ▼ -22.6% |
| 2011 | -1.62x | $-5.39 Million | $3.32 Million | ▲ +9.9% |
| 2010 | -1.80x | $-7.70 Million | $4.28 Million | ▲ +66.5% |
| 2009 | -5.37x | $-15.28 Million | $2.84 Million | ▲ +3.6% |
| 2008 | -5.57x | $-27.58 Million | $4.95 Million | ▲ +20.7% |
| 2007 | -7.03x | $-23.87 Million | $3.40 Million | ▼ -38.7% |
| 2006 | -5.07x | $-14.79 Million | $2.92 Million | ▲ +43.0% |
| 2005 | -8.89x | $-9.10 Million | $1.02 Million | ▼ -164.8% |
| 2004 | -3.36x | $-2.31 Million | $689.70K | ▼ -104.8% |
| 2003 | -1.64x | $-157.60K | $96.18K | ▼ -2399.4% |
| 2002 | -0.07x | $-105.83K | $1.61 Million | ▼ -8.2% |
| 2001 | -0.06x | $-81.81K | $1.35 Million | ▲ +9.7% |
| 2000 | -0.07x | $-80.09K | $1.19 Million | ▼ -105.3% |
| 1999 | -0.03x | $-35.22K | $1.08 Million | ▼ -92.0% |
| 1998 | -0.02x | $-46.15K | $2.71 Million | ▼ -1100.9% |
| 1997 | 0.00x | $4.56K | $2.68 Million | — |